Newron Pharmaceuticals SpA (NWRN) Price & Analysis

Compare

4 Followers

NWRN Stock Chart & Stats

CHF19.26

-CHF0.12(-1.32%)

At close: Mar 06 4:00 PM EST

CHF19.26

-CHF0.12(-1.32%)

Day’s Range― - ―

52-Week RangeCHF5.20 - CHF31.85

Previous CloseN/A

Volume17.86K

Average Volume (3M)170.30K

Market Cap

CHF420.31M

Enterprise ValueCHF446.41M

Total Cash (Recent Filing)CHF43.20M

Total Debt (Recent Filing)CHF52.57M

Price to Earnings (P/E)16.2

Beta1.98

Next Earnings

Mar 24, 2026

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding20,014,585

10 Day Avg. Volume255,106

30 Day Avg. Volume170,297

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)121.21

Price to Sales (P/S)3.44

P/FCF Ratio-10.03

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF42.74

Price Target Upside121.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentInitiation of the ENIGMA-TRS 2 pivotal trial following FDA and IRB authorizations advances the global Phase 3 program and supports enrollment of at least 400 diverse patients across multiple regions.

Intellectual PropertyEuropean Patent Office granted an additional composition-of-matter patent for evenamide and national-phase filings in key countries extend exclusivity and delay generic competition.

Strategic Acquisition AppealEvenamide's demonstrated efficacy and favorable safety profile, together with strong strategic interest in neuropsychiatry assets, increases the company's attractiveness to potential acquirers.

Bears Say

Market Concentration RiskDependence on success in U.S. and European markets concentrates the drug's value and exposes the company's valuation to regional regulatory or commercial setbacks.

Newron Pharmaceuticals SpA News

Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug Evenamide

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has issued an update. Newron Pharmaceuticals has secured commitments of up to...

7d ago

Newron Raises Up to EUR 38 Million to Advance Phase III Schizophrenia Drug

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has shared an announcement. Newron Pharmaceuticals has secured an equity financing package...

7d ago

Newron’s Evenamide Shows Durable Benefits as Add-On Therapy in Treatment-Resistant Schizophrenia

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has provided an announcement. Newron Pharmaceuticals has highlighted a new peer-reviewed publication...

20d ago

Newron Pharma price target raised to CHF 43 from CHF 26 at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Newron Pharma (NWPHF) to CHF 43 from...

1M ago

EA Pharma Starts Phase III Trial of Newron’s Evenamide for Treatment‑Resistant Schizophrenia in Japan

The latest announcement is out from Newron Pharmaceuticals SpA ( ($CH:NWRN) ). Newron Pharmaceuticals’ partner EA Pharma, a...

2M ago

Newron Secures EU Patent Extension for Lead Schizophrenia Drug Evenamide

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has issued an announcement. Newron Pharmaceuticals has secured a new European compound...

2M ago

Newron Wins Long-Term EU Patent Protection for Lead Schizophrenia Drug Evenamide

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has provided an update. Newron Pharmaceuticals has secured a new European compound...

2M ago

Newron Pharma initiated with a Buy at Lucid Capital

Lucid Capital analyst Elemer Piros initiated coverage of Newron Pharma (NWPHF) with a Buy rating and CHF 73...

2M ago

Newron Pharmaceuticals’ Evenamide Advances with ENIGMA-TRS 2 Trial: Analyst Reiterates Buy Rating

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Newron Pharmaceuticals SpA,...

2M ago

Newron Pharma initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Newron Pharma (NWPHF) with a Buy rating and CHF 26 price target The...

3M ago

Newron Pharmaceuticals Launches Phase III Study for Schizophrenia Treatment

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) just unveiled an announcement. Newron Pharmaceuticals has announced the US launch of...

3M ago

Newron Pharmaceuticals’ Phase III Study on Evenamide: A Potential Game-Changer for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals SpA (($NWPHF)) announced an update on their ongoing clinical study. Study Overview: Newron Pharmaceuticals SpA is...

4M ago

NWPHF

Newron Pharmaceuticals Advances Evenamide for Schizophrenia Treatment

Newron Pharmaceuticals SpA ( ($CH:NWRN) ) has shared an announcement. Newron Pharmaceuticals announced the presentation of new analyses...

5M ago

Newron Pharma upgraded to Buy from Add at Baader Helvea

Baader Helvea upgraded Newron Pharma to Buy from Add with a CHF 13.60 price target. Published first on...

2y ago

NWRN FAQ

What was Newron Pharmaceuticals SpA’s price range in the past 12 months?

Newron Pharmaceuticals SpA lowest stock price was CHF5.20 and its highest was CHF31.85 in the past 12 months.

What is Newron Pharmaceuticals SpA’s market cap?

Newron Pharmaceuticals SpA’s market cap is CHF420.31M.

When is Newron Pharmaceuticals SpA’s upcoming earnings report date?

Newron Pharmaceuticals SpA’s upcoming earnings report date is Mar 24, 2026 which is in 29 days.

How were Newron Pharmaceuticals SpA’s earnings last quarter?

Newron Pharmaceuticals SpA released its earnings results on Sep 16, 2025. The company reported CHF0 earnings per share for the quarter, beating the consensus estimate of -CHF0.38 by CHF0.38.

Is Newron Pharmaceuticals SpA overvalued?

According to Wall Street analysts Newron Pharmaceuticals SpA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Newron Pharmaceuticals SpA pay dividends?

Newron Pharmaceuticals SpA does not currently pay dividends.

What is Newron Pharmaceuticals SpA’s EPS estimate?

Newron Pharmaceuticals SpA’s EPS estimate is -0.07.

How many shares outstanding does Newron Pharmaceuticals SpA have?

Newron Pharmaceuticals SpA has 20,014,585 shares outstanding.

What happened to Newron Pharmaceuticals SpA’s price movement after its last earnings report?

Newron Pharmaceuticals SpA reported an EPS of CHF0 in its last earnings report, beating expectations of -CHF0.38. Following the earnings report the stock price went up 6.257%.

Which hedge fund is a major shareholder of Newron Pharmaceuticals SpA?

Currently, no hedge funds are holding shares in CH:NWRN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Newron Pharmaceuticals SpA

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Newron Pharmaceuticals SpA (NWRN) Earnings & Revenues

Historic Earnings Reports

NWRN Stock 12 Month Forecast

Average Price Target

CHF42.74

▲(121.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"CHF5","24":"CHF24","43":"CHF43","14.5":"CHF14.5","33.5":"CHF33.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42.74231480619232,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF42.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.7398535828,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF42.74</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.74231480619232,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF42.74</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,14.5,24,33.5,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20,21.749408831245564,23.498817662491128,25.248226493736688,26.99763532498225,28.747044156227815,30.496452987473376,32.245861818718936,33.9952706499645,35.74467948121007,37.49408831245563,39.24349714370119,40.99290597494675,{"y":42.74231480619232,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20,21.74921950636923,23.498439012738462,25.24765851910769,26.996878025476924,28.746097531846154,30.495317038215383,32.24453654458462,33.99375605095385,35.74297555732308,37.49219506369231,39.241414570061536,40.990634076430766,{"y":42.7398535828,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20,21.749408831245564,23.498817662491128,25.248226493736688,26.99763532498225,28.747044156227815,30.496452987473376,32.245861818718936,33.9952706499645,35.74467948121007,37.49408831245563,39.24349714370119,40.99290597494675,{"y":42.74231480619232,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.04,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.76,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.55,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.28,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.89,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.92,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.44,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.44,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.85,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >